Monistat 3 Related Published Studies
Well-designed clinical trials related to Monistat 3 (Miconazole Vaginal)
Multicenter, double-blind, parallel group study investigating the non-inferiority
of efficacy and safety of a 2% miconazole nitrate shampoo in comparison with a 2%
ketoconazole shampoo in the treatment of seborrhoeic dermatitis of the scalp. [2014]
Multicenter, double-blind, parallel group study investigating the non-inferiority
of efficacy and safety of a 2% miconazole nitrate shampoo in comparison with a 2%
ketoconazole shampoo in the treatment of seborrhoeic dermatitis of the scalp. [2014]
Efficacy and tolerability of sertaconazole nitrate 2% cream vs. miconazole in patients with cutaneous dermatophytosis. [2011.05]
Miconazole oral gel increases exposure to oral oxycodone by inhibition of CYP2D6 and CYP3A4. [2011.03]
Randomized, comparative, double-blind, double-dummy, multicenter trial of miconazole buccal tablet and clotrimazole troches for the treatment of oropharyngeal candidiasis: study of miconazole Lauriad(R) efficacy and safety (SMiLES). [2010.07]
Antimicrobial central venous catheters in oncology: efficacy of a rifampicin-miconazole-releasing catheter. [2010.04]
Randomized, comparative, double-blind, double-dummy, multicenter trial of
miconazole buccal tablet and clotrimazole troches for the treatment of
oropharyngeal candidiasis: study of miconazole Lauriad® efficacy and safety
(SMiLES). [2010]
Sertaconazole 2% cream vs. miconazole 2% cream for cutaneous mycoses: a double-blind clinical trial. [2009.12]
Oral voriconazole and miconazole oral gel produce comparable effects on the pharmacokinetics and pharmacodynamics of etoricoxib. [2009.01]
Safety and efficacy of bedtime versus daytime administration of the miconazole nitrate 1200 mg vaginal ovule insert to treat vulvovaginal candidiasis. [2005.01]
Comparison of dermatopharmacokinetic vs. clinicial efficacy methods for bioequivalence assessment of miconazole nitrate vaginal cream, 2% in humans. [2002.03]
[Efficacy and tolerance of 200 mg of fenticonazole versus 400 mg of miconazole in the intravaginal treatment of mycotic vulvovaginitis] [2002.02]
Single-dose miconazole nitrate vaginal ovule in the treatment of vulvovaginal candidiasis: two single-blind, controlled studies versus miconazole nitrate 100 mg cream for 7 days. [2000.05]
A comparative clinical evaluation of econazole nitrate, miconazole, and nystatin in the treatment of vaginal candidiasis. [2000.01]
Butoconazole nitrate 2% for vulvovaginal candidiasis. New, single-dose vaginal cream formulation vs. seven-day treatment with miconazole nitrate. Gynazole 1 Study Group. [1999.11]
Shorter treatment for vaginal candidosis: comparison between single-dose oral fluconazole and three-day treatment with local miconazole. [1992.11]
Single-dose oral fluconazole versus single-dose topical miconazole for the treatment of acute vulvovaginal candidosis. [1990]
Comparison of three-day butoconazole treatment with seven-day miconazole treatment for vulvovaginal candidiasis. [1989.07]
Well-designed clinical trials possibly related to Monistat 3 (Miconazole Vaginal)
The contraceptive vaginal ring, NuvaRing, and antimycotic co-medication. [2004.02]
Terconazole for the treatment of vulvovaginal candidiasis. [1990.11]
Other research related to Monistat 3 (Miconazole Vaginal)
Randomized Trial of Periodic Presumptive Treatment With High-Dose Intravaginal
Metronidazole and Miconazole to Prevent Vaginal Infections in HIV-negative Women. [2015]
Efficacy and tolerability of sertaconazole nitrate 2% cream vs. miconazole in
patients with cutaneous dermatophytosis. [2011]
Systemic uptake of miconazole during vaginal suppository use and effect on CYP1A2 and CYP3A4 associated enzyme activities in women. [2010.12]
In vitro profiling of pramiconazole and in vivo evaluation in Microsporum canis dermatitis and Candida albicans vaginitis laboratory models. [2010.11]
L(9) orthogonal design assisted formulation and evaluation of chitosan-based buccoadhesive films of miconazole nitrate. [2009.07]
Efficacy and tolerance of metronidazole and miconazole nitrate in treatment of vaginitis. [2008.09]
The effect of ambulation on vaginal distribution of miconazole nitrate (1200 mg). [2007.06]
Miconazole: a historical perspective. [2006.04]
Effect of vaginal metronidazole + miconazole treatment during pregnancy for gestational age and birth weight in a population-based study. [2005.10]
The possible association between the combination of vaginal metronidazole and miconazole treatment and poly-syndactyly Population-based case-control teratologic study. [2005.05]
Difference in percutaneous absorption and intracutaneous distribution in guinea pigs among topical antifungal drugs (tioconazole solution, tioconazole cream, miconazole nitrate solution and bifonazole solution). [2004.09]
Vaginal distribution of miconazole nitrate suspension from administration of a single vaginal insert. [2004.02]
[Vaginal candidiasis--treatment protocols using miconazole and fluconazole] [2003]
Bioavailability study of a 1200 mg miconazole nitrate vaginal ovule in healthy female adults. [2002.01]
Efficacy of 7-day treatment with metronidazole+miconazole (Neo-Penotran) - a triple-active pessary for the treatment of single and mixed vaginal infections. [2001.07]
Swelling-controlled release system for the vaginal delivery of miconazole. [2000.11]
Potentiation of warfarin's hypoprothrombinemic effect with miconazole vaginal suppositories. [2000.01]
Miconazole-induced fatal dysrhythmia. [1997.03]
Oral ketoconazole and miconazole vaginal pessary treatment for vaginal candidosis. [1991.08]
Recurrent vaginal candidosis: prospective study of effectiveness of maintenance miconazole treatment. [1988.04]
Other possibly related research studies
A retrospective cost-effectiveness analysis of the treatment of onychomycosis in general practice. [1998.10]
A study of 72 patients with contact allergy to tioconazole. [1996.04]
Contact allergy to tioconazole. [1992.03]
The treatment of onychomycosis with a new form of tioconazole. [1988.06]
Vaginal Candida parapsilosis: pathogen or bystander? [2005.03]
Usage of antifungal drugs for therapy of genital Candida infections, purchased as over-the-counter products or by prescription: I. Analyses of a unique database. [2004.06]
[Candidiasis and birth canal injuries] [2002]
Vaginitis due to Candida krusei: epidemiology, clinical aspects, and therapy. [2002.11.01]
Systemic antifungal agents. [2001.07]
Vulvovaginitis in healthy women. [1999.06]
One-day therapy for vaginal candidiasis. A review. [1999.06]
Over-the-counter and alternative medicines in the treatment of chronic vaginal symptoms. [1997.07]
A new method of antibiotyping yeasts for subspecies discrimination and distribution in human clinical specimens. [1996.02]
[Damage to condoms caused by vaginally administered drug] [1995.08.05]
Physicians' perceptions of the impact of the reclassification of vaginal antifungal agents. [1994.02]
Sch 39304, a new antifungal agent: oral and topical treatment of vaginal and superficial infections. [1993]
Is there a role for fluconazole in the treatment of vulvovaginal candidiasis? [1992.03]
The in vitro activity of terconazole against yeasts: its topical long-acting therapeutic efficacy in experimental vaginal candidiasis in rats. [1991.10]
Imidazoles for vaginitis. [1991.07]
A study of candidosis: the role of fomites. [1991.04]
In vivo efficacy of SM-8668 (Sch 39304), a new oral triazole antifungal agent. [1990.06]
In vivo activity of sertaconazole in experimental candidiasis in the mouse. [1990]
Terconazole--a new antifungal agent for vulvovaginal candidiasis. [1989.09]
Clinical evaluation of terconazole. United states experience. [1989.08]
Clinical evaluation of terconazole. European experience. [1989.08]
[Advantages of single-dose treatment of vaginal Candida albicans infection] [1989.01]
New class of antifungal agents: jasplakinolide, a cyclodepsipeptide from the marine sponge, Jaspis species. [1988.08]
Three-day treatment of vulvovaginal candidiasis. [1988.04]
[Deep vaginal mycosis--a diagnostically and therapeutically re- fractory disease] [1988]
Activity of terbinafine in experimental fungal infections of laboratory animals. [1987.10]
[Anti-Candida activity of azoles] [1987]
Topical fenticonazole in dermatology and gynaecology: current role in therapy. [2008]
[Evaluation of susceptibility to antifungal agents of fungal strains isolated from pregnant women with diabetes and healthy pregnant women] [2009.04]
Susceptibility profile of vaginal isolates of Candida albicans prior to and following fluconazole introduction - impact of two decades. [2009.06.26]
Sertaconazole: a review of its use in the management of superficial mycoses in dermatology and gynaecology. [2009]
Comparison of two shampoos for the treatment of canine Malassezia dermatitis: a randomised controlled trial. [2011.11]
Liquid chromatographic and spectrophotometric determination of diflucortolone valerate and isoconazole nitrate in creams. [2011.01]
Enhancement of drug solubility and absorption by copolymers of 2-methacryloyloxyethyl phosphorylcholine and n-butyl methacrylate. [2011]
Effects of antifungal drugs and delivery vehicles on morphology and proliferation of equine corneal keratocytes in vitro. [2010.08]
Antimicrobial activity of topical skin pharmaceuticals - an in vitro study. [2010.05]
Chronic monolateral otomycosis in a dog caused by Aspergillus ochraceus. [2010.10]
Use of antifungal agents for oral candidiasis: results of a national survey. [2010.02]
Fungal keratitis in a gopher tortoise (Gopherus polyphemus). [2009.09]
Susceptibility profile of vaginal isolates of Candida albicans prior to and following fluconazole introduction - impact of two decades. [2011.01]
Superficial distribution and identification of antifungal/antimicrobial agents on a modified tissue conditioner by SEM-EDS microanalysis: a preliminary study. [2009.10]
Contact sensitization in venous eczema: preliminary results of patch testing with Indian standard series and topical medicaments. [2009.03]
Evidence-based veterinary dermatology: a systematic review of interventions for Malassezia dermatitis in dogs. [2009.02]
Boric acid for recurrent vulvovaginal candidiasis: the clinical evidence. [2011.08]
Boric acid for recurrent vulvovaginal candidiasis: the clinical evidence. [2011]
High-dose vaginal metronidazole for recurrent bacterial vaginosis--a pilot study. [2014]
Prophylactic systemic antifungal agents to prevent mortality and morbidity in
very low birth weight infants. [2013]
|